Patents and other proprietary rights are important to our business. Our policy is to file patent applications to protect our intellectual property rights. Maxygen seeks patent protection for its product candidates in the U.S. and other selected jurisdictions. MAXY G34 (G-CSF)
Maxygen retains all rights to the MAXY-G34 program for commercial
development of all therapeutic areas, including all rights for
chemotherapy-induced neutropenia and ARS indications.
|
